A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Trial ID or NCT#
Status
Purpose
To determine the long-term (approximately 2 years) nephroprotective potential of treatment with sparsentan as compared to an angiotensin receptor blocker in patients with immunoglobulin A nephropathy (IgAN).
Official Title
A Randomized, Multicenter, Double-blind, Parallel-group, Active-control Study of the Efficacy and Safety of Sparsentan for the Treatment of Immunoglobulin A Nephropathy
Eligibility Criteria
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Brittany Yeung
650-498-3116
View on ClinicalTrials.gov